Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 285 matching trials from the live ClinicalTrials.gov search.
Conditions
Papillomavirus Infections, Warts, Condylomata Acuminata, Epidermodysplasia Verruciformis
Interventions
PURELL VF481, Placebo Solution
Other
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions
paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Respiratory Tract Diseases, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Squamous Cell, Tumor Virus Infections, Infections, Virus Diseases, DNA Virus Infections, Pathologic Processes, Disease Attributes, Recurrence, Papilloma, Respiratory Tract Infections, Papillomavirus Infections
Interventions
Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
Interventions
PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

NCT06611540
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
Conditions
Warts
Interventions
CANDIN, Placebo
Biological · Other
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Encinitas, California + 11 more
Completed No phase listed Observational Results available

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

NCT01364896
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions
Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
HPV Infection, Preventive Health Services
Interventions
Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Wichita, Kansas
Completed Not applicable Interventional Accepts healthy volunteers

Research in Ethno-Medicine and Education (REMED)

NCT05907187
Conditions
Cervical Cancer, Human Papilloma Virus, HPV, Human Papillomavirus Infection
Interventions
Cervical Cancer Prevention Education
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2047
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
13 Years to 26 Years · Male only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Best Practice, HPV Self-Collection, Informational Intervention, Patient Navigation Program
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Human Papillomavirus Infection
Interventions
Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Albany, New York • Madison, Wisconsin
Conditions
FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Conditions
Genital Human Papilloma Virus Infection
Interventions
Gardasil
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more